Abstract
Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals and cannot be determined before the final pathologic evaluation. The aim of this study was to identify germline genetic markers that could predict sensitivity or resistance to preoperative radiochemotherapy (RT-CT) in rectal cancer. We evaluated the predictive value of 128 single-nucleotide polymorphisms (SNPs) in 71 patients preoperatively treated by RT-CT. The selected SNPs were distributed over 76 genes that are involved in various cellular processes such as DNA repair, apoptosis, proliferation or immune response. The SNPs superoxide dismutase 2 (SOD2) rs4880 (P=0.005) and interleukin-13 (IL13) rs1800925 (P=0.0008) were significantly associated with tumor response to chemoradiation. These results reinforce the idea of using germline polymorphisms for personalized treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731–1740.
Sauer R . Adjuvant and neoadjuvant radiotherapy and concurrent radiochemotherapy for rectal cancer. Pathol Oncol Res 2002; 8: 7–17.
Crane CH, Skibber JM, Feig BW, Vauthey J, Thames HD, Curley SA et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 2003; 97: 517–524.
Gerard J, Chapet O, Nemoz C, Hartweig J, Romestaing P, Coquard R et al. Improved sphincter preservation in low rectal cancer with high-dose preoperative radiotherapy: the lyon R96-02 randomized trial. J Clin Oncol 2004; 22: 2404–2409.
Ruo L, Tickoo S, Klimstra D, Minsky B, Saltz L, Mazumdar M et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002; 236: 75–81.
Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23: 8688–8696.
Capirci C, Valentini V, Cionini L, De Paoli A, Rodel C, Glynne-Jones R et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99–107.
Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ . Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 2006; 32: 55–64.
Kuremsky JG, Tepper JE, McLeod HL . Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 2009; 74: 673–688.
Spindler KG, Nielsen JN, Lindebjerg J, Jakobsen A . Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 2007; 50: 1363–1369.
Grube D . Constants and variables in immunohistochemistry. Arch Histol Cytol 2004; 67: 115–134.
The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789–796.
Ulrich CM, Robien K, McLeod HL . Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003; 3: 912–920.
Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J . Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol 2005; 54: 171–196.
Dworak O, Keilholz L, Hoffmann A . Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19–23.
Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res 2006; 34: D617–D621.
González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X et al. SNPassoc: an R package to perform whole genome association studies. Bioinformatics 2007; 23: 644–645.
Storey JD, Tibshirani R . Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100: 9440–9445.
Wright S . Adjusted p-values for simultaneous inference. Biometrics 1992; 48: 1005–1013.
Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K et al. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007; 297: 489–498.
Oberley LW . Mechanism of the tumor suppressive effect of MnSOD overexpression. Biomed Pharmacother 2005; 59: 143–148.
Wang CY, Mayo MW, Baldwin AS . TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 1996; 274: 784–787.
Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA . Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003; 22: 5813–5827.
Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y . Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson′s disease. Biochem Biophys Res Commun 1996; 226: 561–565.
Sutton A, Imbert A, Igoudjil A, Descatoire V, Cazanave S, Pessayre D et al. The manganese superoxide dismutase Ala16Val dimorphism modulates both mitochondrial import and mRNA stability. Pharmacogenet Genomics 2005; 15: 311–319.
Terabe M, Park JM, Berzofsky JA . Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 2004; 53: 79–85.
Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA . Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008; 57: 907–912.
Cameron L, Webster RB, Strempel JM, Kiesler P, Kabesch M, Ramachandran H et al. Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C>T, a polymorphism associated with allergic inflammation. J Immunol 2006; 177: 8633–8642.
Demaria S, Bhardwaj N, McBride WH, Formenti SC . Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005; 63: 655–666.
Ménard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F . Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008; 57: 1579–1587.
Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122–1129.
Ho-Pun-Cheung A, Assenat E, Thezenas S, Bibeau F, Rouanet P, Azria D et al. Cyclin D1 gene G870A polymorphism predicts response to neoadjuvant radiotherapy and prognosis in rectal cancer. Int J Radiat Oncol Biol Phys 2007; 68: 1094–1101.
Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR et al. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. J Clin Oncol 2009; 27: 1592–1599.
Wu X, Gu J, Wu T, Swisher SG, Liao Z, Correa AM et al. Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 2006; 24: 3789–3798.
Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 2007; 56: 281–288.
Acknowledgements
This work was supported by Merck Santé and the ANRT (Association Nationale de la Recherche Technique).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Ho-Pun-Cheung, A., Assenat, E., Bascoul-Mollevi, C. et al. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer. Pharmacogenomics J 11, 437–443 (2011). https://doi.org/10.1038/tpj.2010.62
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2010.62
Keywords
This article is cited by
-
Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis
The Pharmacogenomics Journal (2016)
-
Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy
Scientific Reports (2016)
-
Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review
European Journal of Clinical Pharmacology (2015)
-
Évaluation de la réponse histologique dans les cancers du rectum localement avancés après traitement néoadjuvant
Côlon & Rectum (2014)
-
KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment
Modern Pathology (2012)